Anticancer therapeutic strategies for targeting mutant p53-Y220C

Abstract

The tumor suppressor p53 is a transcription factor with a powerful antitumor activity that is controlled by its negative regulator murine double minute 2 (MDM2, also termed HDM2 in humans) through a feedback mechanism. At the same time, TP53 is the most frequently mutated gene in human cancers. Mutant p53 proteins lose wild-type p53 tumor suppression functions but acquire new oncogenic properties, among which are deregulating cell proliferation, increasing chemoresistance, disrupting tissue architecture, and promoting migration, invasion and metastasis as well as several other pro-oncogenic activities. The oncogenic p53 mutation Y220C creates an extended surface crevice in the DNA-binding domain destabilizing p53 and causing its denaturation and aggregation. This cavity accommodates stabilizing small molecules that have therapeutic values. The development of suitable small-molecule stabilizers is one of the therapeutic strategies for reactivating the Y220C mutant protein. In this review, we summarize approaches that target p53-Y220C, including reactivating this mutation with small molecules that bind Y220C to the hydrophobic pocket and developing immunotherapies as the goal for the near future, which target tumor cells that express the p53-Y220C neoantigen.

Keywords

p53 / Y220C mutation / small molecule / DNA-binding domain / immunotherapy / T cell receptor mimic antibody

Fundings

This research was funded by the Ministry of Science and Higher Education of the Russian Federation (Grant No. 075-15-2020-795 of 29.09.2020, unique project ID: RF-190220X0027).

Acknowledgments

None.

References

[1] Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a[J]. Cell, 1997, 88(5): 593-602. doi: 10.1016/S0092-8674(00)81902-9

[2] Shaw P, Bovey R, Tardy S, et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line[J]. Proc Natl Acad Sci U S A, 1992, 89(10): 4495-4499. doi: 10.1073/pnas.89.10.4495

[3] Yin Y, Tainsky MA, Bischoff FZ, et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles[J]. Cell, 1992, 70(6): 937-948. doi: 10.1016/0092-8674(92)90244-7

[4] Banin S, Moyal L, Shieh SY, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage[J]. Science, 1998, 281(5383): 1674-1677. doi: 10.1126/science.281.5383.1674

[5] Meek DW. Multisite phosphorylation and the integration of stress signals at p53[J]. Cell Signal, 1998, 10(3): 159-166. doi: 10.1016/S0898-6568(97)00119-8

[6] Subhasree N, Qin J, Srivenugopal KS, et al. The MDM2-p53 pathway revisited[J]. J Biomed Res, 2013, 27(4): 254-271. doi: 10.7555/JBR.27.20130030

[7] Wu X, Bayle JH, Olson D, et al. The p53-mdm-2 autoregulatory feedback loop[J]. Genes Dev, 1993, 7(7A): 1126-1132. doi: 10.1101/gad.7.7a.1126

[8] Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types[J]. Nature, 2013, 502(7471): 333-339. doi: 10.1038/nature12634

[9] Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell[J]. Cell Death Differ, 2019, 26(2): 199-212. doi: 10.1038/s41418-018-0246-9

[10] Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants[J]. Oncogene, 2007, 26(15): 2226-2242. doi: 10.1038/sj.onc.1210291

[11] Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users[J]. Hum Mutat, 2002, 19(6): 607-614. doi: 10.1002/humu.10081

[12] Bullock AN, Henckel J, DeDecker BS, et al. Thermodynamic stability of wild-type and mutant p53 core domain[J]. Proc Natl Acad Sci U S A, 1997, 94(26): 14338-14342. doi: 10.1073/pnas.94.26.14338

[13] di Como CJ, Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay[J]. Oncogene, 1998, 16(19): 2527-2539. doi: 10.1038/sj.onc.1202041

[14] Dearth LR, Qian H, Wang T, et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers[J]. Carcinogenesis, 2007, 28(2): 289-298. doi: 10.1093/carcin/bgl132

[15] Joerger AC, Ang HC, Fersht AR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs[J]. Proc Natl Acad Sci U S A, 2006, 103(41): 15056-15061. doi: 10.1073/pnas.0607286103

[16] Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database[J]. Hum Mutat, 2007, 28(6): 622-629. doi: 10.1002/humu.20495

[17] Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy[J]. Oncogene, 2000, 19(10): 1245-1256. doi: 10.1038/sj.onc.1203434

[18] Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53[J]. Annu Rev Biochem, 2008, 77: 557-582. doi: 10.1146/annurev.biochem.77.060806.091238

[19] Malekzadeh P, Pasetto A, Robbins PF, et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers[J]. J Clin Invest, 2019, 129(3): 1109-1114. doi: 10.1172/JCI123791

[20] Malekzadeh P, Yossef R, Cafri G, et al. Antigen experienced T cells from peripheral blood recognize p53 neoantigens[J]. Clin Cancer Res, 2020, 26(6): 1267-1276. doi: 10.1158/1078-0432.CCR-19-1874

[21] Dao T, Klatt MG, Korontsvit T, et al. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer[J]. Cancer Immunol Immunother, 2021, 70(5): 1189-1202. doi: 10.1007/s00262-020-02764-9

[22] Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations[J]. Science, 1994, 265(5170): 346-355. doi: 10.1126/science.8023157

[23] Loh SN. Follow the mutations: toward class-specific, small-molecule reactivation of p53[J]. Biomolecules, 2020, 10(2): 303. doi: 10.3390/biom10020303

[24] Timofeev O, Stiewe T. Rely on each other: DNA binding cooperativity shapes p53 functions in tumor suppression and cancer therapy[J]. Cancers, 2021, 13(10): 2422. doi: 10.3390/cancers13102422

[25] Eldar A, Rozenberg H, Diskin-Posner Y, et al. Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions[J]. Nucleic Acids Res, 2013, 41(18): 8748-8759. doi: 10.1093/nar/gkt630

[26] Wang G, Fersht AR. Multisite aggregation of p53 and implications for drug rescue[J]. Proc Natl Acad Sci U S A, 2017, 114(13): E2634-E2643. doi: 10.1073/pnas.1700308114

[27] Gaiddon C, Lokshin M, Ahn J, et al. A subset of tumor-derived mutant forms of p 53 down-regulate p63 and p73 through a direct interaction with the p53 core domain[J]. Mol Cell Biol, 2001, 21(5): 1874-1887. doi: 10.1128/MCB.21.5.1874-1887.2001

[28] Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation[J]. Cell, 1991, 65(5): 765-774. doi: 10.1016/0092-8674(91)90384-B

[29] Oren M, Rotter V. Mutant p53 gain-of-function in cancer[M]. New York: Cold Spring Harbor Laboratory Press, 2010: a001107.

[30] Müller P, Ceskova P, Vojtesek B. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy[J]. J Biol Chem, 2005, 280(8): 6682-6691. doi: 10.1074/jbc.M412767200

[31] Loh SN. The missing zinc: p53 misfolding and cancer[J]. Metallomics, 2010, 2(7): 442-449. doi: 10.1039/c003915b

[32] Wang G, Fersht AR. First-order rate-determining aggregation mechanism of p53 and its implications[J]. Proc Natl Acad Sci U S A, 2012, 109(34): 13590-13595. doi: 10.1073/pnas.1211557109

[33] Yu X, Vazquez A, Levine AJ, et al. Allele-specific p53 mutant reactivation[J]. Cancer Cell, 2012, 21(5): 614-625. doi: 10.1016/j.ccr.2012.03.042

[34] Blanden AR, Yu X, Loh SN, et al. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer[J]. Drug Discov Today, 2015, 20(11): 1391-1397. doi: 10.1016/j.drudis.2015.07.006

[35] Weekley CM, He C. Developing drugs targeting transition metal homeostasis[J]. Curr Opin Chem Biol, 2017, 37: 26-32. doi: 10.1016/j.cbpa.2016.12.011

[36] Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches[J]. Annu Rev Biochem, 2016, 85: 375-404. doi: 10.1146/annurev-biochem-060815-014710

[37] Guiley KZ, Shokat KM. A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability[J]. Cancer Discov, 2023, 13(1): 56-69. doi: 10.1158/2159-8290.cd-22-0381

[38] Wilcken R, Wang G, Boeckler FM, et al. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition[J]. Proc Natl Acad Sci U S A, 2012, 109(34): 13584-13589. doi: 10.1073/pnas.1211550109

[39] D’Orazi G, Givol D. p53 reactivation: the link to zinc[J]. Cell Cycle, 2012, 11(14): 2581-2582. doi: 10.4161/cc.21020

[40] Barros EP, Demir Ö, Soto J, et al. Markov state models and NMR uncover an overlooked allosteric loop in p53[J]. Chem Sci, 2020, 12(5): 1891-1900. doi: 10.1039/d0sc05053a

[41] Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2[J]. Science, 2004, 303(5659): 844-848. doi: 10.1126/science.1092472

[42] Aguilar A, Wang S. Therapeutic strategies to activate p53[J]. Pharmaceuticals, 2023, 16(1): 24. doi: 10.3390/ph16010024

[43] Jung J, Lee JS, Dickson MA, et al. TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma[J]. Nat Commun, 2016, 7: 12609. doi: 10.1038/ncomms12609

[44] Lu J, Chen L, Song Z, et al. Hypothermia effectively treats tumors with temperature-sensitive p53 mutations[J]. Cancer Res, 2021, 81(14): 3905-3915. doi: 10.1158/0008-5472.CAN-21-0033

[45] Lehmann S, Bykov VJN, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer[J]. J Clin Oncol, 2012, 30(29): 3633-3639. doi: 10.1200/JCO.2011.40.7783

[46] Bykov VJN, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound[J]. Nat Med, 2002, 8(3): 282-288. doi: 10.1038/nm0302-282

[47] Bykov VJN, Zache N, Stridh H, et al. PRIMA-1^MET synergizes with cisplatin to induce tumor cell apoptosis[J]. Oncogene, 2005, 24(21): 3484-3491. doi: 10.1038/sj.onc.1208419

[48] Mohell N, Alfredsson J, Fransson Å, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells[J]. Cell Death Dis, 2015, 6(6): e1794. doi: 10.1038/cddis.2015.143

[49] Bykov VJN, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic[J]. FEBS Lett, 2014, 588(16): 2622-2627. doi: 10.1016/j.febslet.2014.04.017

[50] Degtjarik O, Golovenko D, Diskin-Posner Y, et al. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)[J]. Nat Commun, 2021, 12(1): 7057. doi: 10.1038/s41467-021-27142-6

[51] Peng X, Zhang MQZ, Conserva F, et al. APR-246/PRIMA-1^MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase[J]. Cell Death Dis, 2013, 4(10): e881. doi: 10.1038/cddis.2013.417

[52] Xu J, Reumers J, Couceiro JR, et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors[J]. Nat Chem Biol, 2011, 7(5): 285-295. doi: 10.1038/nchembio.546

[53] Paz MM, Ferretti GDS, Martins-Dinis MMC, et al. PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma[J]. Front Mol Biosci, 2023, 10: 1165132. doi: 10.3389/fmolb.2023.1165132

[54] Wang Z, Hu H, Heitink L, et al. The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells[J]. Cell Death Differ, 2023, 30(4): 1033-1046. doi: 10.1038/s41418-023-01122-3

[55] Salim KY, Vareki SM, Danter WR, et al. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo[J]. Oncotarget, 2016, 7(27): 41363-41379. doi: 10.18632/oncotarget.9133

[56] Silver NL, Osman AA, Patel AA, et al. A novel third generation thiosemicarbazone, COTI-2, is highly effective in killing head and neck squamous cell carcinomas (HNSCC) bearing a variety of TP53 mutations[J]. Int J Radiat Oncol Biol Phys, 2016, 94(4): 942. doi: 10.1016/j.ijrobp.2015.12.272

[57] Lindemann A, Patel AA, Silver NL, et al. COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms[J]. Clin Cancer Res, 2019, 25(18): 5650-5662. doi: 10.1158/1078-0432.CCR-19-0096

[58] Maleki Vareki S, Salim KY, Danter WR, et al. Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines[J]. PLoS One, 2018, 13(1): e0191766. doi: 10.1371/journal.pone.0191766

[59] Bauer MR, Joerger AC, Fersht AR. 2-sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells[J]. Proc Natl Acad Sci U S A, 2016, 113(36): E5271-E5280. doi: 10.1073/pnas.1610421113

[60] Boeckler FM, Joerger AC, Jaggi G, et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug[J]. Proc Natl Acad Sci U S A, 2008, 105(30): 10360-10365. doi: 10.1073/pnas.0805326105

[61] Liu X, Wilcken R, Joerger AC, et al. Small molecule induced reactivation of mutant p53 in cancer cells[J]. Nucleic Acids Res, 2013, 41(12): 6034-6044. doi: 10.1093/nar/gkt305

[62] Bauer MR, Jones RN, Tareque RK, et al. A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C[J]. Future Med Chem, 2019, 11(19): 2491-2504. doi: 10.4155/fmc-2019-0181

[63] Baud MGJ, Bauer MR, Verduci L, et al. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines[J]. Eur J Med Chem, 2018, 152: 101-114. doi: 10.1016/j.ejmech.2018.04.035

[64] Clarke JRS, Douglas LR, Duriez PJ, et al. Discovery of nanomolar-affinity pharmacological chaperones stabilizing the oncogenic p53 mutant Y220C[J]. ACS Pharmacol Transl Sci, 2022, 5(11): 1169-1180. doi: 10.1021/acsptsci.2c00164

[65] Wilcken R, Liu X, Zimmermann MO, et al. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53[J]. J Am Chem Soc, 2012, 134(15): 6810-6818. doi: 10.1021/ja301056a

[66] Miller JJ, Orvain C, Jozi S, et al. Multifunctional compounds for activation of the p53-Y220C mutant in cancer[J]. Chemistry, 2018, 24(67): 17734-17742. doi: 10.1002/chem.201802677

[67] Miller JJ, Kwan K, Blanchet A, et al. Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C[J]. J Inorg Biochem, 2023, 242: 112164. doi: 10.1016/j.jinorgbio.2023.112164

[68] Sundar D, Yu Y, Katiyar SP, et al. Wild type p53 function in p53Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence[J]. J Exp Clin Canc Res, 2019, 38(1): 103. doi: 10.1186/s13046-019-1099-x

[69] Malhotra L, Sharma S, Hariprasad G, et al. Mechanism of apoptosis activation by Curcumin rescued mutant p53Y220C in human pancreatic cancer[J]. Biochim Biophys Acta Mol Cell Res, 2022, 1869(12): 119343. doi: 10.1016/j.bbamcr.2022.119343

[70] Radhakrishnan N, Dhanjal JK, Sari AN, et al. Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53^Y220C mutant: bioinformatics and experimental evidence[J]. Discov Oncol, 2021, 12(1): 64. doi: 10.1007/s12672-021-00461-2

[71] Garg S, Singh J, Verma SR. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics[J]. J Mol Model, 2023, 29(2): 55. doi: 10.1007/s00894-023-05454-2

[72] Puzio-Kuter AM, Mulligan C, Russo B, et al. Abstract 1295: small molecule reactivators of Y220C mutant p53 modulate tumor infiltrating leukocytes and synergize with immune checkpoint inhibitors[J]. Cancer Res, 2022, 82(12_Supplement): 1295. doi: 10.1158/1538-7445.AM2022-1295

[73] Dumble M, Xu L, Dominique R, et al. Abstract LB006: PC14586: the first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development[J]. Cancer Res, 2021, 81(13S): LB006. doi: 10.1158/1538-7445.am2021-lb006

[74] Dumbrava EE, Johnson ML, Tolcher AW, et al. First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation[J]. J Clin Oncol, 2022, 40(16S): 3003. doi: 10.1200/jco2022

[75] Gannon JV, Greaves R, Iggo R, et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form[J]. EMBO J, 1990, 9(5): 1595-1602. doi: 10.1002/j.1460-2075.1990.tb08279.x

[76] Legros Y, Meyer A, Ory K, et al. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein[J]. Oncogene, 1994, 9(12): 3689-3694. https://pubmed.ncbi.nlm.nih.gov/7526318/

[77] Yolcu E, Sayan BS, Yağci T, et al. A monoclonal antibody against DNA binding helix of p53 protein[J]. Oncogene, 2001, 20(11): 1398-1401. doi: 10.1038/sj.onc.1204240

[78] Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy[J]. Curr Opin Mol Ther, 2009, 11(1): 22-30. https://pubmed.ncbi.nlm.nih.gov/19169956/

[79] Li D, Bentley C, Anderson A, et al. Development of a T-cell receptor mimic antibody against wild-type p53 for cancer immunotherapy[J]. Cancer Res, 2017, 77(10): 2699-2711. doi: 10.1158/0008-5472.CAN-16-3247

[80] Hsiue EHC, Wright KM, Douglass J, et al. Targeting a neoantigen derived from a common TP53 mutation[J]. Science, 2021, 371(6533): eabc8697. doi: 10.1126/science.abc8697

[81] Amelio I, Melino G, Levine AJ. Bispecific antibodies come to the aid of cancer immunotherapy[J]. Mol Oncol, 2021, 15(7): 1759-1763. doi: 10.1002/1878-0261.12977

[82] Deniger DC, Pasetto A, Robbins PF, et al. T-cell responses to TP53 "hotspot" mutations and unique neoantigens expressed by human ovarian cancers[J]. Clin Cancer Res, 2018, 24(22): 5562-5573. doi: 10.1158/1078-0432.CCR-18-0573

[83] Ye C, Lin S, Hong J, et al. Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma[J]. Eur J Immunol, 2023, 53(5): 2250054. doi: 10.1002/eji.202250054

[84] Webb ES, Liu P, Baleeiro R, et al. Immune checkpoint inhibitors in cancer therapy[J]. J Biomed Res, 2018, 32(5): 317-326. doi: 10.7555/JBR.31.20160168

[85] Dong ZY, Zhong W, Zhang X, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma[J]. Clin Cancer Res, 2017, 23(12): 3012-3024. doi: 10.1158/1078-0432.CCR-16-2554

[86] Kobold S, Pantelyushin S, Rataj F, et al. Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy[J]. Front Oncol, 2018, 8: 285. doi: 10.3389/fonc.2018.00285

[87] Middelburg J, Kemper K, Engelberts P, et al. Overcoming challenges for CD3-bispecific antibody therapy in solid tumors[J]. Cancers, 2021, 13(2): 287. doi: 10.3390/cancers13020287

[88] Groeneveldt C, Kinderman P, van den Wollenberg DJM, et al. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy[J]. J Immunother Cancer, 2020, 8(2): e001191. doi: 10.1136/jitc-2020-001191